Receptor del factor de crecimiento de fibroblastos (FGFR)
Los inhibidores de FGFR (receptores del factor de crecimiento de fibroblastos) son terapias dirigidas que bloquean la actividad de los FGFR, los cuales están involucrados en la proliferación celular, diferenciación y angiogénesis. La señalización de FGFR contribuye a la formación de nuevos vasos sanguíneos en los tumores, promoviendo su crecimiento y supervivencia. Inhibir FGFR puede, por lo tanto, reducir la angiogénesis y la progresión tumoral. En CymitQuimica, ofrecemos una gama de inhibidores de FGFR de alta calidad para apoyar su investigación en cáncer, biología del desarrollo y angiogénesis.
Se han encontrado 170 productos de "Receptor del factor de crecimiento de fibroblastos (FGFR)"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
FGFR1 inhibitor-2
CAS:<p>FGFR1 inhibitor-2, potent at 4.55 μM IC50 in MDA-MB-231, targets triple-negative breast cancer.</p>Fórmula:C25H22F5N3O3Forma y color:SolidPeso molecular:507.461Fazpilodemab
CAS:<p>Fazpilodemab (BFKB8488A) is a humanized bispecific antibody that targets and activates the Klotho β and fibroblast growth factor receptor 1c receptor complex.</p>Forma y color:LiquidFGFR1 inhibitor 7
<p>FGFR1 Inhibitor 7 (compound 5), a potent FGFR1 tyrosine kinase inhibitor, exhibits an IC50 of 0.33 nM against its target and demonstrates broad-spectrum</p>Fórmula:C25H16ClNO4Pureza:98%Forma y color:SolidPeso molecular:429.85PKCε (85-92)
CAS:<p>PKCε (85-92) (ψεRACK) is a peptide and selective PKCε activator, induces a pro-angiogenic response, promotes FGF-2 cytosolization, regulates VEGF activity.</p>Fórmula:C39H54N10O14Pureza:98.71%Forma y color:SolidPeso molecular:886.91IMC-D11
<p>IMC-D11 (LY-3076226 antibody) is an IgG1 monoclonal antibody targeting FGFR3. It serves as the antibody component of LY3076226. For its isotype control, refer to Human IgG1 kappa, Isotype Control.</p>Forma y color:Odour LiquidEfimosfermin alfa
<p>Efimosfermin alfa is a humanized antibody targeting FGFR1.</p>Forma y color:Odour LiquidVofatamab
CAS:<p>Vofatamab (B-701) is a fully human monoclonal antibody targeting FGFR3, often used in combination with other compounds to treat cancer.</p>Pureza:> 95% - > 95%Forma y color:LiquidPeso molecular:150 kDaRecifercept
CAS:<p>Recifercept (TA-46) is a recombinant human soluble fibroblast growth factor receptor 3, a decoy protein that competes for ligands of mutant FGFR3.</p>Pureza:98.8% (SDS-PAGE); 98.4% (SEC-HPLC) - 98.8% (SDS-PAGE); 98.4% (SEC-HPLC)Forma y color:LiquidLC-MB12
CAS:<p>LC-MB12 is a PROTAC FGFR2 compound that degrades FGFR2 and can be used to study gastric cancer.</p>Fórmula:C43H44Cl2N10O8Pureza:99.16%Forma y color:SolidPeso molecular:899.78Gunagratinib
CAS:<p>Gunagratinib (ICP-192) is a pan-FGFR inhibitor, useful in research on FGFR-related diseases.</p>Fórmula:C22H25N5O4Pureza:99.68%Forma y color:SolidPeso molecular:423.47E7090
CAS:<p>E-7090 is a fibroblast growth factor receptor inhibitor. E-7090 is a selective inhibitor of the tyrosine kinase activities of FGFR1, -2, and -3.</p>Fórmula:C32H37N5O6Forma y color:SolidPeso molecular:587.67FGFR4-IN-14
<p>FGFR4-IN-14 (Compound 27i) is a selective FGFR4 inhibitor with an IC50 of 2.4 nM, showing potent inhibition of cell proliferation in the V550L and N535K mutant</p>Fórmula:C27H25Cl2N5O2Pureza:98%Forma y color:SolidPeso molecular:522.43BW710
<p>BW710 is an orally active inhibitor specifically targeting fibroblast growth factor receptor 2 (FGFR2). It effectively inhibits the proliferation of BaF3-FGFR2 cells with an IC50 value of 2.8 nM. BW710 completely suppresses FGFR2 enzymatic activity and demonstrates selectivity among 75 tyrosine kinases, including FGFR1, FGFR3, and FGFR4, at a 1 μM concentration. Additionally, BW710 impedes FGFR2 signaling and selectively inhibits the proliferation of cancer cells driven by FGFR2. It exhibits promising pharmacokinetic properties, with an oral bioavailability of 29% in mice.</p>Fórmula:C28H29FN6O2SForma y color:SolidPeso molecular:532.63FGFR-IN-19
<p>Arg-IN-1 is a selective covalent inhibitor targeting Arginine (Arg), with IC50 values of 9.7 nM and 30.4 nM for FGFR2 and FGFR3, respectively. This compound is designed to potentially avoid the off-target toxicity of FGFR1/4 and overcome acquired resistance, offering potential in cancer therapies targeting FGFR.</p>Fórmula:C36H42N12O6Forma y color:SolidPeso molecular:738.33503FGFR1 inhibitor-8
<p>FGFR1 inhibitor-8 (Compound 9), an FGFR1 inhibitor with an IC50 of 0.5 nM, binds to the ATP-binding pocket of FGFR1 and exhibits anticancer activity [1].</p>Fórmula:C26H18ClNO5Pureza:98%Forma y color:SolidPeso molecular:459.88FGFR1/VEGFR2-IN-1
<p>FGFR1/VEGFR2-IN-1 (compound 2b) is an inhibitor of both FGFR1 and VEGFR2, applicable in cancer research [1].</p>Fórmula:C26H27N4O6PPureza:98%Forma y color:SolidPeso molecular:522.49FGFR2 degrader 1
<p>FGFR2 degrader1 (compound 28E) is a selective PROTACS degrader of FGFR2, with a DC50 of 0.645 nM. FGFR2 plays a significant role in cancer research.</p>Fórmula:C40H39Cl2N9O6Peso molecular:811.24004PROTAC FGFR1 degrader-1
<p>PROTAC FGFR1 degrader-1 (compound S2H) is a targeted degrader of FGFR1, demonstrating an IC50 of 26.81 nM and a DC50 of 39.78 nM in KG1a cells. This compound is composed of a CRBN-type E3 ligase ligand (blue part) Pomalidomide, a target protein ligand (red part) FGFR1ligand-1, and a PROTAC linker (black part) 9-Bromononanoic acid, together forming the conjugate E3LigaseLigand-linker Conjugate 164.</p>Fórmula:C46H54N8O8Forma y color:SolidPeso molecular:846.97Nintedanib
CAS:Fórmula:C31H33N5O4Pureza:>95.0%(T)(HPLC)Forma y color:White to Yellow to Yellow green powder to crystalPeso molecular:539.64NSC 12
CAS:<p>NSC 12 is an orally active pan-FGF trap that binds FGF2 and interferes with its interaction with FGFR1 with potential FGF-dependent antitumor activity.</p>Fórmula:C24H34F6O3Pureza:99.51%Forma y color:SolidPeso molecular:484.52
